Neural Cell News Volume 16.21 | Jun 1 2022

June 1, 2022

2022-06-01 | NCN 16.21

Neural Cell News by STEMCELL Technologies

Vol. 16.21 – 1 June, 2022

TOP STORY

Neuronal NLRP3 Is a Parkin Substrate That Drives Neurodegeneration in Parkinson’s Disease

Researchers showed that loss of parkin activity in mouse and human dopamine (DA) neurons resulted in spontaneous neuronal NOD-like receptor protein 3 (NLRP3) inflammasome assembly, leading to DA neuron death.
[Neuron]

Abstract Graphical Abstract

Survey results on the insights and hurdles of CRISPR genome editing.

PUBLICATIONSRanked by the impact factor of the journal

Proteomic Phenotype of Cerebral Organoids Derived from Autism Spectrum Disorder Patients Reveal Disrupted Energy Metabolism, Cellular Components, and Biological Processes

Cerebral organoids derived from autism spectrum disorder patients were generated to capture critical time-points in the neuronal development, and metabolism and protein expression were investigated.
[Molecular Psychiatry]

Abstract

Robust Derivation of Transplantable Dopamine Neurons From Human Pluripotent Stem Cells by Timed Retinoic Acid Delivery

Researchers outlined an approach for high-yield derivation of mesencephalic dopamine neurons that principally differed from alternative technologies by utilizing retinoic acid signaling, instead of WNT and FGF8 signaling, to specify mesencephalic fate.
[Nature Communications]

Full Article

Purine Nucleoside Phosphorylase Deficiency Induces p53-Mediated Intrinsic Apoptosis in Human Induced Pluripotent Stem Cell-Derived Neurons

The authors investigated the cause of diverse non-infectious neurologic abnormalities, in which induced pluripotent stem cells from two purine nucleoside phosphorylase-deficient patients were differentiated into neurons.
[Scientific Reports]

Full Article

Human Cerebral Spheroids Undergo 4-Aminopyridine-Induced, Activity Associated Changes in Cellular Composition and Microrna Expression

Investigators used cerebral spheroids derived from human induced pluripotent stem cells to investigate the effects of 4-aminopyridine on neuronal activity and associated neurogenesis.
[Scientific Reports]

Full Article

JCI-20679 Suppresses the Proliferation of Glioblastoma Stem Cells by Activating AMPK and Decreasing NFATc2 Expression Levels

Scientists demonstrated that JCI‑20679 inhibited the growth of glioblastoma stem cells derived from a transposon system‑mediated murine glioblastoma model more efficiently compared with the growth of differentiation‑induced adherent cells.
[Molecular Medicine Reports]

Abstract

A Labroots 2021 Webinar: iPSCs As Models, Part 2: Modeling the Human Brain with Organoids, presented by Dr. Anjana Nityanandam, Director of the Human Stem Cell Lab core facility at St. Jude Children’s Research Hospital. Click to Watch Now.

REVIEWS

Altered Neural Cell Junctions and Ion-Channels Leading to Disrupted Neuron Communication in Parkinson’s Disease

The authors emphasize how, alongside α-synuclein, ion-channels, gap-junctions, and related connexins all play vital roles in influencing multiple metabolic activities of the brain during Parkinson’s disease.
[npj Parkinson’s Disease]

Full Article

INDUSTRY AND POLICY NEWS

Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA^® (pembrolizumab) in Newly Diagnosed Glioblastoma

Novocure announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc. to study the use of Tumor Treating Fields concomitant with MSD’s anti-PD-1 therapy KEYTRUDA^® for the treatment of patients with newly diagnosed glioblastoma.
[Novocure]

Press Release

FDA Grants AlgoTx IND Clearance for Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

European biotech AlgoTx announced that the US FDA cleared its Investigational New Drug Application (IND) for Phase II candidate ATX01 in the treatment of chemotherapy-induced peripheral neuropathy.
[AlgoTherapeutix SAS (Business Wire, Inc.)]

Press Release

FEATURED EVENT

Neural Cell News Volume 16.21 | Jun 1 2022

Neuronal NLRP3 Is a Parkin Substrate That Drives Neurodegeneration in Parkinson’s Disease

Proteomic Phenotype of Cerebral Organoids Derived from Autism Spectrum Disorder Patients Reveal Disrupted Energy Metabolism, Cellular Components, and Biological Processes

Robust Derivation of Transplantable Dopamine Neurons From Human Pluripotent Stem Cells by Timed Retinoic Acid Delivery

Purine Nucleoside Phosphorylase Deficiency Induces p53-Mediated Intrinsic Apoptosis in Human Induced Pluripotent Stem Cell-Derived Neurons

Human Cerebral Spheroids Undergo 4-Aminopyridine-Induced, Activity Associated Changes in Cellular Composition and Microrna Expression

JCI-20679 Suppresses the Proliferation of Glioblastoma Stem Cells by Activating AMPK and Decreasing NFATc2 Expression Levels

Altered Neural Cell Junctions and Ion-Channels Leading to Disrupted Neuron Communication in Parkinson’s Disease

Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA^® (pembrolizumab) in Newly Diagnosed Glioblastoma

FDA Grants AlgoTx IND Clearance for Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

The Neuro-Immune Axis

> See All Events

Senior Scientist – Bioinformatics, Neuroscience and Drug Discovery

Postdoctoral Fellow – Multiple Sclerosis

Tenured Full Professor – Neurology

Research Associate – Astrocytoma Pathogenesis

Postdoctoral Associate – Molecular Neuroscience and Disease

> See All Jobs